August 15, 2016
Teijin said on August 10 that it has obtained exclusive rights in Japan to develop and commercialize somavaratan (VRS-317), a long-acting form of a recombinant growth hormone (rhGH) being developed by US biopharma Versartis, for all potential indications. Versartis is...read more